200433-00-7

Upstream product

• 171046-44-9 1-(4,5-diphenyloxazol-2-yl)-1-cyclohexene 
• 3144-09-0 methanesulfonamide 

Downstream Products

• 200433-01-8 (1R,2S)-1-(4,5-diphenyl-oxazol-2-yl)-1,2-epoxycyclohexane 
• 171045-79-7 ethyl (S)-{3-{[2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl}phenoxy}acetate 
• 652976-37-9 3-[(S)-2-(4,5-Diphenyl-oxazol-2-yl)-cyclohex-2-enylmethyl]-phenol 
• 171046-75-6 (S)-2-(4,5-diphenyloxazol-2-yl)-1-(3-methoxybenzyl)-2-cyclohexene 

Relevant academic research and scientific papers

A simple stereoselective synthesis and biological evaluation of FR181157: Orally active prostacyclin mimetic

Synthetic method of novel prostaglandin (PG) mimetic: FR181175 without PG skeleton are described. The key to success is creation of a chiral epoxide using Sharpless AD reaction with high ee yield. FR181157 shows high potency and agonist efficacy at the IP receptor and has good bioavailability.

Oxazole compounds useful as PGE2 agonists and antagonists

Azole compounds of the formula: wherein R1 is lower alkyl substituted with carboxy, etc.,R2 is hydrogen or lower alkyl,R3 is aryl, etc.R4 is aryl, etc.Q is ?etc., andX is O, NH or S,and its salt, which are usefu